1
Sudhir Agrawal, Qiuyan Zhao: Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal. Hybridon, Law Offices of Wayne A Keown, July 30, 2002: US06426334 (99 worldwide citation)

The invention provides new methods for modulating specific CMI-inducing cytokines in vivo. Such new methods result in stimulation of the cytokines IL-6, IL-12 MIP-1&bgr; and MCP without substantially inducing undesired cytokines. The methods according to the invention are based upon administration o ...


2
Sudhir Agrawal, Ekambar R Kandimalla, Dong Yu, Lakshmi Bhagat: Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends. Idera Pharmaceuticals, Keown & Zucchero, Wayne A Keown, Joseph C Zucchero, October 2, 2007: US07276489 (93 worldwide citation)

The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers ...


3
Jacob Vromen: Formulations for topical delivery of bioactive substances and methods for their use. Australian Importers, Keown & Zucchero, Wayne A Keown, Joseph C Zucchero, July 10, 2007: US07241456 (25 worldwide citation)

The invention relates to topical delivery of bioactive agents. More particularly, the invention relates to anhydrous formulations for percutaneous absorption. The invention provides formulations that allow efficient topical delivery of high concentrations of bioactive substances for percutaneous abs ...


4
Sudhir Agrawal, Ekambar R Kandimalla, Dong Yu, Lakshmi Bhagat: Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends. Idera Pharmaceuticals, Keown & Zucchero, Wayne A Keown, Joseph C Zucchero, August 5, 2008: US07407944 (23 worldwide citation)

The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers ...


5
Radhakrishnan P Iyer, Theresa Devlin, Ivan Habus, Dong Yu, Sudhir Agrawal: Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same. Hybridon, Wayne A Keown, Hale and Dorr, October 31, 2000: US06140482 (23 worldwide citation)

The invention provides new primary phosphoramidate internucleoside linkages that are less sterically constrained than existing phosphoramidate linkages, as well as oligonucleotides containing such linkages and processes for making and methods for using such oligonucleotides.


6
Sudhir Agrawal, Ekambar R Kandimalla, Dong Yu, Lakshmi Bhagat: Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends. Idera Pharmaceuticals, Keown & Zucchero, Wayne A Keown, Joseph C Zucchero, April 14, 2009: US07517862 (22 worldwide citation)

The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers ...


7
Ekambar R Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal: Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes. Idera Pharmaceuticals, Joseph C Zucchero, Wayne A Keown, August 28, 2007: US07262286 (20 worldwide citation)

The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.


8
Sudhir Agrawal, Ekambar Kandimalla, Dong Yu: Immunostimulatory oligonucleotide multimers. Idera Pharmaceuticals, Keown & Zucchero, Wayne A Keown, Joseph C Zucchero, July 29, 2008: US07405285 (16 worldwide citation)

The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.


9
Jacob Vromen: Cosmetic compositions comprising exfoliating enzymes and uses thereof. Australian Importers, Law Offices of Wayne A Keown, July 9, 2002: US06416769 (14 worldwide citation)

Cosmetic compositions for topical use that comprise an exfoliating enzyme for use in removal of at least a portion of the dead skin cells from the outer layer of skin, in conjunction with one or more botanicals, the delivery of which to subsurface layers and cells thereof of the skin is enhanced by ...


10
Sudhir Agrawal: Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides. Idera Pharmacetuicals, Wayne A Keown, Joseph C Zucchero, February 12, 2008: US07329648 (13 worldwide citation)

The invention provides methods for modulating the immune response caused by CpG-containing oligonucleotides. The methods according to the invention enable both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy app ...